GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2021;402:203–34.

Google Scholar 

Chan JCN, Lim LL, Wareham NJ, et al. The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. Lancet. 2021;396:2019–82.

Article  PubMed  Google Scholar 

Ahmad E, Lim S, Lamptey R, et al. Type 2 diabetes. Lancet. 2022;400:1803–20.

Article  PubMed  Google Scholar 

Ye J, Wu Y, Yang S, et al. The global, regional and national burden of type 2 diabetes mellitus in the past, present and future: a systematic analysis of the Global Burden of Disease Study 2019. Front Endocrinol (Lausanne). 2023;14:1192629.

Article  PubMed  Google Scholar 

Abushanab D, Marquina C, Morton JI, et al. Projecting the health and economic burden of cardiovascular disease among people with type 2 diabetes, 2022–2031. Pharmacoeconomics. 2023;41:719–32.

Article  PubMed  PubMed Central  Google Scholar 

Nauck MA, Quast DR, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes—state-of-the-art. Mol Metab. 2021;46: 101102.

Article  CAS  PubMed  Google Scholar 

Scheen AJ. Sodium-glucose co-transporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nature Rev Endocrinol. 2020;16:556–77.

Article  Google Scholar 

Scheen AJ. The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review. Expert Rev Endocrinol Metab. 2023;18:271–82.

Article  CAS  PubMed  Google Scholar 

Karagiannis T, Tsapas A, Bekiari E, et al. A methodological framework for meta-analysis and clinical interpretation of subgroup data: the case of major adverse cardiovascular events with GLP-1 receptor agonists and SGLT2 inhibitors in type 2 diabetes. Diabetes Care. 2024;47:184–92.

Article  CAS  PubMed  Google Scholar 

Scheen AJ. Cardiovascular outcome studies in type 2 diabetes: comparison between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes Res Clin Pract. 2018;143:88–100.

Article  CAS  PubMed  Google Scholar 

Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372: m4573.

Article  PubMed  PubMed Central  Google Scholar 

Giugliano D, Scappaticcio L, Longo M, et al. GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off. Cardiovasc Diabetol. 2021;20:205.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391:109–21.

Article  CAS  PubMed  Google Scholar 

Colhoun HM, Lingvay I, Brown PM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024;30(7):2058–66. 

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scheen AJ. Antidiabetic agents and risk of atrial fibrillation/flutter: a comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes Metab. 2022;48: 101390.

Article  CAS  PubMed  Google Scholar 

Scheen AJ. Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: a comprehensive review ranging from sulphonylureas to SGLT2 inhibitors. Diabetes Metab. 2022;48: 101405.

Article  CAS  PubMed  Google Scholar 

Scheen AJ. Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke? Discordance between randomised controlled trials and observational studies. Diabetes Metab. 2023;49: 101474.

Article  CAS  PubMed  Google Scholar 

Caruso I, Cignarelli A, Sorice GP, et al. Cardiovascular and renal effectiveness of GLP-1 receptor agonists vs. other glucose-lowering drugs in type 2 diabetes: a systematic review and meta-analysis of real-world studies. Metabolites. 2022;12:183.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Forbes AK, Suckling RJ, Hinton W, et al. Sodium-glucose cotransporter-2 inhibitors and kidney outcomes in real-world type 2 diabetes populations: a systematic review and meta-analysis of observational studies. Diabetes Obes Metab. 2023;25:2310–30.

Article  CAS  PubMed  Google Scholar 

Hinton W, Ansari AS, Whyte MB, et al. Sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: are clinical trial benefits for heart failure reflected in real-world clinical practice? A systematic review and meta-analysis of observational studies. Diabetes Obes Metab. 2023;25:501–15.

Article  CAS  PubMed  Google Scholar 

Lee YS, Jun HS. Anti-inflammatory effects of GLP-1-based therapies beyond glucose control. Mediators Inflamm. 2016;2016:3094642.

Article  PubMed  PubMed Central  Google Scholar 

Rowlands J, Heng J, Newsholme P, et al. Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function. Front Endocrinol (Lausanne). 2018;9:672.

Article  PubMed  Google Scholar 

Muller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72–130.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Andreasen CR, Andersen A, Knop FK, et al. How glucagon-like peptide 1 receptor agonists work. Endocr Connect. 2021;10:R200–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma X, Liu Z, Ilyas I, et al. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. Int J Biol Sci. 2021;17:2050–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pandey S, Mangmool S, Parichatikanond W. Multifaceted roles of GLP-1 and its analogs: a review on molecular mechanisms with a cardiotherapeutic perspective. Pharmaceuticals (Basel). 2023;16:836.

Article  CAS  PubMed  Google Scholar 

Yau K, Odutayo A, Dash S, et al. Biology and clinical use of glucagon-like peptide-1 receptor agonists in vascular protection. Can J Cardiol. 2023;39:1816–38.

Article  PubMed  Google Scholar 

Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60:215–25.

Article  CAS  PubMed  Google Scholar 

Patel DK, Strong J. The pleiotropic effects of sodium-glucose cotransporter-2 inhibitors: beyond the glycemic benefit. Diabetes Ther. 2019;10:1771–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ojha U, Reyes L, Eyenga F, et al. Diabetes, heart failure and beyond: elucidating the cardioprotective mechanisms of sodium glucose cotransporter 2 (SGLT2) inhibitors. Am J Cardiovasc Drugs. 2022;22:35–46.

Article  CAS  PubMed  Google Scholar 

Rastogi A, Januzzi JL Jr. Pleiotropic effects of sodium-glucose cotransporter-2 inhibitors in cardiovascular disease and chronic kidney disease. J Clin Med. 2023;12:2824.

Article  CAS  PubMed  PubMed Central